Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

A new species of Euchaetes Harris from southern Arizona (Erebidae, Arctiinae).

Nagle RB, Schmidt BC.

Zookeys. 2018 Oct 8;(788):69-77. doi: 10.3897/zookeys.788.26310. eCollection 2018.

PMID:
30337824
2.

Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer.

Das L, Gard JMC, Prekeris R, Nagle RB, Morrissey C, Knudsen BS, Miranti CK, Cress AE.

Mol Cancer Res. 2018 Aug;16(8):1319-1331. doi: 10.1158/1541-7786.MCR-17-0589. Epub 2018 May 14.

PMID:
29759989
3.

Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?

Rice PFS, Ehrichs KG, Jones MS, Chen H, Hsu CH, Abril ER, Nagle RB, Besselsen DG, Barton JK, Ignatenko NA.

Cancer Prev Res (Phila). 2018 Jan;11(1):16-26. doi: 10.1158/1940-6207.CAPR-17-0230. Epub 2017 Nov 8.

PMID:
29118162
4.

Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort.

Nguyen MM, Martinez JA, Hsu CH, Sokoloff M, Krouse RS, Gibson BA, Nagle RB, Parnes HL, Cordova C, Chow HS.

Eur J Cancer Prev. 2018 Nov;27(6):557-562. doi: 10.1097/CEJ.0000000000000394.

PMID:
28692586
5.

The Cohesive Metastasis Phenotype in Human Prostate Cancer.

Harryman WL, Hinton JP, Rubenstein CP, Singh P, Nagle RB, Parker SJ, Knudsen BS, Cress AE.

Biochim Biophys Acta. 2016 Dec;1866(2):221-231. doi: 10.1016/j.bbcan.2016.09.005. Epub 2016 Sep 24. Review.

6.

A basal cell defect promotes budding of prostatic intraepithelial neoplasia.

Wang M, Nagle RB, Knudsen BS, Rogers GC, Cress AE.

J Cell Sci. 2017 Jan 1;130(1):104-110. doi: 10.1242/jcs.188177. Epub 2016 Sep 8.

7.

Characterization of Laminin Binding Integrin Internalization in Prostate Cancer Cells.

Das L, Anderson TA, Gard JM, Sroka IC, Strautman SR, Nagle RB, Morrissey C, Knudsen BS, Cress AE.

J Cell Biochem. 2017 May;118(5):1038-1049. doi: 10.1002/jcb.25673. Epub 2017 Jan 5.

8.

Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancers.

Harryman WL, Pond E, Singh P, Little AS, Eschbacher JM, Nagle RB, Cress AE.

Am J Transl Res. 2016 Feb 15;8(2):940-54. eCollection 2016.

9.

Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography.

LeGendre-McGhee S, Rice PS, Wall RA, Sprute KJ, Bommireddy R, Luttman AM, Nagle RB, Abril ER, Farrell K, Hsu CH, Roe DJ, Gerner EW, Ignatenko NA, Barton JK.

Cancer Growth Metastasis. 2015 Sep 7;8(Suppl 1):63-80. doi: 10.4137/CGM.S21216. eCollection 2015.

10.

Schwann Cells Increase Prostate and Pancreatic Tumor Cell Invasion Using Laminin Binding A6 Integrin.

Sroka IC, Chopra H, Das L, Gard JM, Nagle RB, Cress AE.

J Cell Biochem. 2016 Feb;117(2):491-9. doi: 10.1002/jcb.25300.

11.

Combined micro CT and histopathology for evaluation of skeletal metastasis in live animals.

Geffre CP, Pond E, Pond GD, Sroka IC, Gard JM, Skovan BA, Meek WE, Landowski TH, Nagle RB, Cress AE.

Am J Transl Res. 2015 Feb 15;7(2):348-55. eCollection 2015.

12.

Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.

Lucero-Acuña A, Jeffery JJ, Abril ER, Nagle RB, Guzman R, Pagel MD, Meuillet EJ.

Int J Nanomedicine. 2014 Dec 3;9:5653-65. doi: 10.2147/IJN.S68511. eCollection 2014.

13.

Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.

Kacsinta AD, Rubenstein CS, Sroka IC, Pawar S, Gard JM, Nagle RB, Cress AE.

Biochem Biophys Res Commun. 2014 Nov 14;454(2):335-40. doi: 10.1016/j.bbrc.2014.10.073. Epub 2014 Oct 22.

14.

Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis.

Sathyanarayana UG, Birch C, Nagle RB, Tomlins SA, Palanisamy N, Zhang W, Hubbard A, Brunhoeber P, Wang Y, Tang L.

Appl Immunohistochem Mol Morphol. 2015 May-Jun;23(5):364-73. doi: 10.1097/PAI.0000000000000085.

PMID:
25265431
15.

Increased aPKC Expression Correlates with Prostatic Adenocarcinoma Gleason Score and Tumor Stage in the Japanese Population.

Perry AS, Furusato B, Nagle RB, Ghosh S.

Prostate Cancer. 2014;2014:481697. doi: 10.1155/2014/481697. Epub 2014 Apr 29.

16.

Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model.

Landowski TH, Gard J, Pond E, Pond GD, Nagle RB, Geffre CP, Cress AE.

Mol Cancer Ther. 2014 Jun;13(6):1558-66. doi: 10.1158/1535-7163.MCT-13-0962. Epub 2014 Apr 16.

17.

Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas.

Morgan SS, Nagle RB, Cranmer LD.

Clin Sarcoma Res. 2014 Jan 31;4(1):2. doi: 10.1186/2045-3329-4-2.

19.

ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.

Nagle RB, Algotar AM, Cortez CC, Smith K, Jones C, Sathyanarayana UG, Yun S, Riley J, Nagy D, Dittamore R, Dalkin B, Brosh L, Pestano G.

Prostate. 2013 Aug;73(11):1233-40. doi: 10.1002/pros.22675. Epub 2013 May 7.

20.

Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer.

Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP.

Prostate. 2013 Feb 15;73(3):328-35. doi: 10.1002/pros.22573. Epub 2012 Aug 10.

21.

CD44 Promotes Epithelial Mammary Gland Development and Exhibits Altered Localization during Cancer Progression.

Louderbough JM, Brown JA, Nagle RB, Schroeder JA.

Genes Cancer. 2011 Aug;2(8):771-81. doi: 10.1177/1947601911428223.

22.

Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities.

Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, Sokoloff MH, Gretzer MB, Chow HH.

Cancer Prev Res (Phila). 2012 Feb;5(2):290-8. doi: 10.1158/1940-6207.CAPR-11-0306. Epub 2011 Nov 1.

23.

Metastasis Update: Human Prostate Carcinoma Invasion via Tubulogenesis.

Nagle RB, Cress AE.

Prostate Cancer. 2011;2011:249290. doi: 10.1155/2011/249290. Epub 2011 Jun 21.

24.

ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.

Cohen JD, Gard JM, Nagle RB, Dietrich JD, Monks TJ, Lau SS.

Toxicol Sci. 2011 Nov;124(1):75-87. doi: 10.1093/toxsci/kfr203. Epub 2011 Aug 2.

25.

Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer.

Algotar AM, Stratton SP, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Thompson PA.

Am J Mens Health. 2011 May;5(3):272-8. doi: 10.1177/1557988310390030.

26.

Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity.

Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP.

Intern Med J. 2012 Apr;42(4):374-80. doi: 10.1111/j.1445-5994.2011.02473.x.

27.

Dose-dependent effects of selenized yeast on total selenium levels in prostatic tissue of men with prostate cancer.

Algotar AM, Stratton MS, Xu MJ, Dalkin BL, Nagle RB, Hsu CH, Ahmann FR, Clark LC, Stratton SP.

Nutr Cancer. 2011;63(1):1-5. doi: 10.1080/01635581.2010.516476. No abstract available.

28.

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS.

Clin Cancer Res. 2010 Nov 1;16(21):5320-8. doi: 10.1158/1078-0432.CCR-10-0974.

29.

Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas.

Zhang W, McElhinny A, Nielsen A, Wang M, Miller M, Singh S, Rueger R, Rubin BP, Wang Z, Tubbs RR, Nagle RB, Roche P, Wu P, Pestic-Dragovich L.

Appl Immunohistochem Mol Morphol. 2011 Jan;19(1):54-61. doi: 10.1097/PAI.0b013e3181ee8e14.

PMID:
20881839
30.

The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion.

Sroka IC, Anderson TA, McDaniel KM, Nagle RB, Gretzer MB, Cress AE.

J Cell Physiol. 2010 Aug;224(2):283-8. doi: 10.1002/jcp.22149. Review.

31.

Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity.

Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP.

Prostate. 2010 Jun 1;70(8):883-8. doi: 10.1002/pros.21122.

32.

Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

Gordon MS, Hussey M, Nagle RB, Lara PN Jr, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D.

J Clin Oncol. 2009 Dec 1;27(34):5788-93. doi: 10.1200/JCO.2008.18.8821. Epub 2009 Nov 2.

33.

Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.

Ports MO, Nagle RB, Pond GD, Cress AE.

Cancer Res. 2009 Jun 15;69(12):5007-14. doi: 10.1158/0008-5472.CAN-09-0354. Epub 2009 Jun 2.

34.

Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer.

Riley CJ, Engelhardt KP, Saldanha JW, Qi W, Cooke LS, Zhu Y, Narayan ST, Shakalya K, Croce KD, Georgiev IG, Nagle RB, Garewal H, Von Hoff DD, Mahadevan D.

Cancer Res. 2009 Mar 1;69(5):1933-40. doi: 10.1158/0008-5472.CAN-08-2707. Epub 2009 Feb 24.

35.

Human Cell Surface Receptors as Molecular Imaging Candidates for Metastatic Prostate Cancer.

Sroka IC, Pond GD, Nagle RB, Porreca F, King T, Pestano G, Futscher BW, Gard JM, Riley J, Cress AE.

Open Prost Cancer J. 2009 Jan 1;2:59-66.

36.

The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model.

King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Demetriou MC, Nagle RB, Porreca F, Cress AE.

PLoS One. 2008;3(10):e3535. doi: 10.1371/journal.pone.0003535. Epub 2008 Oct 28.

37.

Sympathetic nerves in the tarsal tunnel: implications for blood flow in the diabetic foot.

Blount AL, Peled ZM, Dexter EL, Nagle RB, Maloney CT, Dellon AL.

Plast Reconstr Surg. 2008 Jul;122(1):188-91. doi: 10.1097/PRS.0b013e31817742c3. No abstract available.

PMID:
18594404
38.

Cross-validation of murine UV signal transduction pathways in human skin.

Einspahr JG, Bowden GT, Alberts DS, McKenzie N, Saboda K, Warneke J, Salasche S, Ranger-Moore J, Curiel-Lewandrowski C, Nagle RB, Nickoloff BJ, Brooks C, Dong Z, Stratton SP.

Photochem Photobiol. 2008 Mar-Apr;84(2):463-76. doi: 10.1111/j.1751-1097.2007.00287.x. Epub 2008 Jan 29.

PMID:
18248498
39.

Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression.

Sroka IC, McDaniel K, Nagle RB, Bowden GT.

Prostate. 2008 Apr 1;68(5):463-76. doi: 10.1002/pros.20718.

PMID:
18196535
40.

Integrin A6 Cleavage in Mouse Skin Tumors.

Demetriou MC, Kwei KA, Powell MB, Nagle RB, Bowden GT, Cress AE.

Open Cancer J. 2008 Jan 1;2:1-4.

41.

Quantitative, spatial resolution of the epigenetic field effect in prostate cancer.

Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, Nagle RB, Neri JR, Mazumder A.

Prostate. 2008 Feb 1;68(2):152-60.

PMID:
18058812
42.

Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer.

Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, Worrall L, Gillies RJ.

Br J Cancer. 2007 Sep 3;97(5):646-53. Epub 2007 Aug 7.

43.

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.

Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC.

J Clin Oncol. 2007 Jun 10;25(17):2406-13.

PMID:
17557954
44.

A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.

Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, Scott KM, Brown RW, Grogan T, Roche PC, Tubbs RR.

Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):94-102.

PMID:
17536315
46.

Integrin alpha6 cleavage: a novel modification to modulate cell migration.

Pawar SC, Demetriou MC, Nagle RB, Bowden GT, Cress AE.

Exp Cell Res. 2007 Apr 1;313(6):1080-9. Epub 2007 Jan 17.

47.

Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse.

Ignatenko NA, Holubec H, Besselsen DG, Blohm-Mangone KA, Padilla-Torres JL, Nagle RB, de Alboránç IM, Guillen-R JM, Gerner EW.

Cancer Biol Ther. 2006 Dec;5(12):1658-64. Epub 2006 Dec 7.

PMID:
17106247
48.

Human laminin-5 and laminin-10 mediated gene expression of prostate carcinoma cells.

Calaluce R, Beck SK, Bair EL, Pandey R, Greer KA, Hoying AM, Hoying JB, Mount DW, Nagle RB.

Prostate. 2006 Sep 15;66(13):1381-90.

PMID:
16804886
49.

Expression of mTOR signaling pathway markers in prostate cancer progression.

Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB.

Prostate. 2006 Aug 1;66(11):1203-12.

PMID:
16652388
50.

Stimulated endothelial cell adhesion and angiogenesis with laminin-5 modification of expanded polytetrafluoroethylene.

Kidd KR, Dal Ponte D, Stone AL, Hoying JB, Nagle RB, Williams SK.

Tissue Eng. 2005 Sep-Oct;11(9-10):1379-91.

PMID:
16259593

Supplemental Content

Loading ...
Support Center